Vasomune Therapeutics to Present on Vascular Leak in Combat-Relevant Injury at the 2026 Military Health System Research Symposium

Article content

Article content

Dr. Harold Kim will discuss Pegevongitide (AV-001), Vasomune’s lead candidate targeting vascular leak, an underlying pathology in injury and illness across casualty care

Article content

Article content

TORONTO — Vasomune Therapeutics, Inc. (“Vasomune”), a clinical-stage biopharmaceutical company developing therapies that target vascular leak, today announced that Dr. Harold Kim, Chief Scientific Officer, will present at the 2026 Military Health System Research Symposium (MHSRS), taking place August 3–6, 2026, at the Gaylord Palms Resort and Convention Center in Kissimmee, Florida. MHSRS is the United States Department of War’s premier scientific meeting focused on addressing medical needs of military service personnel, bringing together military medical providers, scientists, academia, and industry to advance research across combat casualty care and military operational medicine.

Article content

Article content

Date: Tuesday, August 4, 2026

Article content

Article content

Time: 0800–1000 am EST, Hemorrhage Control & Vascular Dysfunction breakout session

Article content

Place: Sun D Hall, Gaylord Palms Resort & Convention Center, FL USA

Article content

Vascular leak, or the breakdown of the endothelial barrier that lines blood vessels, allows fluid and proteins to quickly escape circulation and leak into surrounding tissues, often causing edema and end-organ failure. Vascular leak is a common and deadly underlying pathology seen in conditions of concern to defence and public health authorities such as acute respiratory distress syndrome (ARDS), hemorrhagic shock, trauma and shock following severe burns. Dr. Kim’s presentation will provide an update on Pegevongitide (AV-001), Vasomune’s first-in-class, PEGylated peptide that activates the Tie2 receptor and blocks vascular leak at the source by stabilizing the vascular endothelium. Vasomune is advancing the clinical development of Pegevongitide, through a co-development program with AnGes, Inc.

Article content

“Vascular leak is a common theme that links many types of injuries, from blast trauma and burn injury to infection-driven ARDS,” said Dr. Harold Kim, Chief Scientific Officer at Vasomune. “We are pleased to bring our work on vascular leak to the MHSRS community and to engage directly with the researchers and clinicians who understand the unique medical challenges we are attempting to treat.”

Article content

About Vasomune Therapeutics, Inc.

Article content

Vasomune Therapeutics, Inc., is a private clinical-stage biopharmaceutical company developing the next generation of medicines to boost the body’s ability to defend against vascular leak. Pegevongitide (AV-001), discovered and researched at Sunnybrook Research Institute at Sunnybrook Hospital in Toronto, is a novel investigational medicine being developed by Vasomune Therapeutics under a co-development agreement with AnGes, Inc. [TYO: 4563] to target vascular leak. Pegevongitide is a first-in-class, PEGylated peptide that activates the Tie2 receptor, a transmembrane protein highly expressed on the surface of endothelial cells in the vasculature, thereby blocking vascular leak. Vascular leak, or the breakdown of the endothelial barrier that lines blood vessels, allows fluid and proteins to quickly escape circulation and leak into surrounding tissues, often causing edema and end-organ failure. Vascular leak is a common and deadly underlying pathology seen in a broad range of disease states including bacterial and viral pneumonia, acute respiratory distress syndrome (ARDS), hemorrhagic shock, trauma and shock following severe burns. Vasomune’s corporate headquarters and laboratories are located in Toronto, Canada, with U.S. offices in Raleigh, NC. For more information, please visit www.vasomune.com.

Article content

Article content

About AnGes, Inc.

Article content

AnGes, Inc., a biopharmaceutical company founded in December 1999, focuses on the development of gene-based medicines. The company’s flagship development product and genetic drug, HGF gene therapy products, received Breakthrough Therapy designation from the FDA in 2024. AnGes is currently working on the development of a Tie2 tyrosine kinase receptor agonist for the treatment of vascular leak and an NF-κB decoy oligonucleotide for chronic discogenic lumbar back pain. Furthermore, AnGes acquired EmendoBio in December 2020 to expand its capabilities in genome-editing technologies. For more information, visit https://www.anges.co.jp/en/.

Article content

Article content

Article content

Article content

View source version on businesswire.com:

Article content

Article content

Article content

Contacts

Article content